RGNX 8-K 2026-11-05

REGENXBIO Inc. (RGNX) 8-K dated 2026-11-05 — accession 0001193125-26-448559.

REGENXBIO Inc. (RGNX) is a biotechnology company listed on US.

REGENXBIO Inc. filed a 8-K on 2026-11-05. Accession 0001193125-26-448559.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported RGNX revenue for 2025-12-31 was $170.4M. Net income was -$193.9M. Revenue was up 104.5% from 2024-12-31 to 2025-12-31. RGNX currently screens at market cap $440.4M.

Not investment advice. The RGNX SEC hub lists recent forms. The stock page is the research view.